TEPROTUMUMAB

Brand name:

• Tepezza®

Pharmaceutical company:

AMGEN AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Thyroid Eye Disease (TED)

PBAC Submission type:

New listing (Early Resolution Pathway)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – May 2025

Related medicines:

• TEPROTUMUMAB

Submission received for:

May 2025 PBAC meeting

Opportunity for consumer comment:

Open 30/01/2025 and close 26/03/2025 (see PBS Website)

PBAC meeting:

Held on 09/05/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

18/07/2025

5Lodgement of required documentation:

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---